InSite ties up with Quest on glaucoma test:
This article was originally published in Clinica
Executive Summary
Quest Diagnostics and ophthalmic products company InSite Vision have set up a one-year agreement under which Quest will provide lab services in the US for InSite's OcuGene genetic test for the early prognosis and diagnosis of glaucoma. The OcuGene kit, introduced recently in the US by the Alameda, California company, consists of a pair of buccal brushes used to swab the inside of the patient's cheek. Quest will test the samples for gene mutation at its Nichols Institute site in San Juan Capistrano, California.